TWiV 1090: Clinical update with Dr. Daniel Griffin

February 24, 2024

In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of respiratory syncytial virus before discussing uptake of the RSV vaccine Abrysvo or the monoclonal anti-RSV antibody nirsevimab to prevent severe disease following RSV infection in infants 8 months or younger before going over this week’s influenza virus and SARS-CoV-2 virus statistics, including all circulating variants in the US, examines if self-testing is more accurate than clinician administered Binax rapid diagnostic tests for SARS-CoV-2 infection, if N95 masks need a yearly fitting, how SARS-CoV-2 vaccination impacts the prevalence of long COVID, reviews the CDC guidelines for quarantine/ isolation following SARS-CoV-2 infection, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, why determining the exact number of long COVID incidences is challenging, how the incidence and predictors for fatiguing illness following SARS-CoV-2 infection may used to reenforce the need for public health actions to prevent virus infection and the risks of respiratory pathologies including lung cancer associate with SARS-C0V-2 infection.

Click arrow to play
Download TWiV 1090 (26 MB .mp3, 36 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

Leave a Reply

Your email address will not be published. Required fields are marked *